Our dual-target HCC panel overcame this problem, and its sensitivity to HCC was significantly higher than that of AFP (86.3% vs. 61.64%), particularly for early stage HCC (78.26% vs. 47.83%). This evidence concerns the gene AFP and hepatocellular carcinoma.